SCHEMBL3018878

SCHEMBL3018878

Cc1cc(C)c(C)c(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)c(Cl)c4)cs3)CC2)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.55
MAPT P10636 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
SMN1; SMN2 Q16637 10/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
ABL1 P00519 2/20 0.43
MAPK1 P28482 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009194 0.92 AR (0.47) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3016661 0.92 AR (0.47) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3002120 0.91 AR (0.54) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL15671709 0.91 MAPT (0.52) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3009737 0.90 SMN1; SMN2 (0.46) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3012471 0.89 SMN1; SMN2 (0.57) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3015669 0.89 SMN1; SMN2 (0.46) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3023440 0.87 MAPK1 (0.45) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3010161 0.87 AR (0.56) ARMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3013264 0.87 MAPK1 (0.56) ARMAPTSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885CYP1A2 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.